International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS.
Terrault, N., Berenguer, M., Strasser, S., gadano, adrian, Lilly, L., Samuel, D., … McCaughan, G. W. (2017). International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS. Transplantation.

International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.
Terrault, N. A., McCaughan, G. W., Curry, M. P., Gane, E., Fagiuoli, S., Fung, J., … Berenguer, M. (2017). International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES. Transplantation.

Confirming What We Believed: Reducing and Eliminating Vertical Transmission of Hepatitis B.
Kligman, E., & Kwo, P. Y. (2017). Confirming What We Believed: Reducing and Eliminating Vertical Transmission of Hepatitis B. Gastroenterology.

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Kwo, P., Gane, E. J., Peng, C.-Y., Pearlman, B., Vierling, J. M., Serfaty, L., … Haber, B. (2017). Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology, 152(1), 164–75 e4.

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology, 112(1), 18–35.

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112(1), 17–36.

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates
Terrault, N. A., McCaughan, G. W., Curry, M. P., Gane, E., Fagiuoli, S., Fung, J. Y. Y., … Berenguer, M. (2017). International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. TRANSPLANTATION, 101(5), 945–55.

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients
Terrault, N. A., Berenguer, M., Strasser, S. I., gadano, adrian, Lilly, L., Samuel, D., … McCaughan, G. W. (2017). International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. TRANSPLANTATION, 101(5), 956–67.

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo, P. Y., Poordad, F., Asatryan, A., Wang, S., Wyles, D. L., Hassanein, T., … Mensa, F. J. (2017). Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. Journal of Hepatology.

Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded
Liangpunsakul, S., & Kwo, P. Y. (2017). Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 15(2), 289–91.

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database
Reddy, K. R., Lim, J. K., Kuo, A., Di Bisceglie, A. M., Galati, J. S., Morelli, G., … Manns, M. P. (2017). All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 45(1), 115–26.

After the Direct-acting Antivirals Are Gone, There Is Still Work to Be Done in the Liver
Kwo, P. Y., & Lacerda, M. A. (2016). After the Direct-acting Antivirals Are Gone, There Is Still Work to Be Done in the Liver. GASTROENTEROLOGY, 151(4), 582–84.

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis
Gane, E., Poordad, F., Wang, S., Asatryan, A., Kwo, P. Y., Lalezari, J., … Mensa, F. J. (2016). High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. GASTROENTEROLOGY, 151(4), 651-?

Hepatic arterial buffer response: pathologic evidence in non-cirrhotic human liver with extrahepatic portal vein thrombosis
Rush, N., Sun, H., Nakanishi, Y., Mneimneh, W., Kwo, P. Y., & Saxena, R. (2016). Hepatic arterial buffer response: pathologic evidence in non-cirrhotic human liver with extrahepatic portal vein thrombosis. MODERN PATHOLOGY, 29(5), 489–99.

Risk factors for bleeding after liver biopsy
Sandrasegaran, K., Thayalan, N., Thavanesan, R., Kohli, M., Berry, W., Shah, A., & Kwo, P. (2016). Risk factors for bleeding after liver biopsy. ABDOMINAL RADIOLOGY, 41(4), 643–49.

Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study
Kwo, P., Gitlin, N., Nahass, R., Bernstein, D., Etzkorn, K., Rojter, S., … Witek, J. (2016). Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study. HEPATOLOGY, 64(2), 370–80.

Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
Chan, H. L. Y., Ahn, S. H., Chang, T.-T., Peng, C.-Y., Wong, D., Coffin, C. S., … Cooney, E. (2016). Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). JOURNAL OF HEPATOLOGY, 64(5), 1011–19.

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
Curry, M. P., O'Leary, J. G., Bzowej, N., Muir, A. J., Korenblat, K. M., Fenkel, J. M., … Charlton, M. (2015). Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. NEW ENGLAND JOURNAL OF MEDICINE, 373(27), 2618–28.

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
Alqahtani, S. A., Afdhal, N., Zeuzem, S., Gordon, S. C., Mangia, A., Kwo, P., … Sulkowski, M. (2015). Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. HEPATOLOGY, 62(1), 25–30.

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Charlton, M., Everson, G. T., Flamm, S. L., Kumar, P., Landis, C., Brown, R. S., … Afdhal, N. (2015). Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. GASTROENTEROLOGY, 149(3), 649–59.

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
Poordad, F., Sievert, W., Mollison, L., Bennett, M., Tse, E., Braeu, N., … Yin, P. D. (2015). Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 313(17), 1728–35.

Narrow-band imaging versus white light for the detection of proximal colon serrated lesions: a randomized, controlled trial
Rex, D. K., Clodfelter, R., Rahmani, F., Fatima, H., James-Stevenson, T. N., Tang, J. C., … Kwo, P. Y. (2016). Narrow-band imaging versus white light for the detection of proximal colon serrated lesions: a randomized, controlled trial. GASTROINTESTINAL ENDOSCOPY, 83(1), 166–71.

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
Muir, A. J., Poordad, F., Lalezari, J., Everson, G., Dore, G. J., Herring, R., … Yin, P. D. (2015). Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 313(17), 1736–44.

Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy.
Lasley, F. D., Mannina, E. M., Johnson, C. S., Perkins, S. M., Althouse, S., Maluccio, M., … Cárdenes, H. (2015). Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Practical Radiation Oncology, 5(5), e443–9.

The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma
Umar, N. K., Badshah, M. B., Sandrasegaran, K., Ghabril, M., Agarwal, S., Tann, M., … Kwo, P. Y. (2015). The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma. DIGESTIVE DISEASES AND SCIENCES, 60(7), 2196–2200.

Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity
Burman, B. E., Kwo, P. Y., & Kowdley, K. V. (2014). Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. HEPATOLOGY INTERNATIONAL, 8(3), 352–64.

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
Kwo, P. Y., Mantry, P. S., Coakley, E., Te, H. S., Vargas, H. E., Brown, R., … Forns, X. (2014). An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. NEW ENGLAND JOURNAL OF MEDICINE, 371(25), 2375–82.

The future of hepatitis C virus therapeutics.
Kwo, P. Y. (2014). The future of hepatitis C virus therapeutics. Gastroenterology & Hepatology, 10(7), 433–35.

Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials
Vierling, J. M., Zeuzem, S., Poordad, F., Bronowicki, J.-P., Manns, M. P., Bacon, B. R., … Bruno, S. (2014). Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials. JOURNAL OF HEPATOLOGY, 61(2), 200–209.

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., … Marcellin, P. (2014). Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. NEW ENGLAND JOURNAL OF MEDICINE, 370(20), 1889–98.

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., … Fried, M. W. (2014). Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. NEW ENGLAND JOURNAL OF MEDICINE, 370(20), 1879–88.

Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant
Kwo, P. Y., Ghabril, M., Lacerda, M. A., Tector, A. J., Fridell, J. A., & Vianna, R. (2014). Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant. CLINICAL TRANSPLANTATION, 28(6), 722–27.

Role of Cardiac Catheterization and Percutaneous Coronary Intervention in the Preoperative Assessment and Management of Patients Before Orthotopic Liver Transplantation
Maddur, H., Bourdillon, P. D., Liangpunsakul, S., Tector, A. J., Fridell, J. A., Ghabril, M., … Kwo, P. Y. (2014). Role of Cardiac Catheterization and Percutaneous Coronary Intervention in the Preoperative Assessment and Management of Patients Before Orthotopic Liver Transplantation. LIVER TRANSPLANTATION, 20(6), 664–72.

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
Manns, M. P., McCone, J., Davis, M. N., Rossaro, L., Schiff, E., Shiffman, M. L., … Vierling, J. M. (2014). Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. LIVER INTERNATIONAL, 34(5), 707–19.

Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
Kowdley, K. V., Lawitz, E., Poordad, F., Cohen, D. E., Nelson, D. R., Zeuzem, S., … Bernstein, B. (2014). Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. NEW ENGLAND JOURNAL OF MEDICINE, 370(3), 222–32.

Ethical Considerations Surrounding Survival Benefit-Based Liver Allocation
Keller, E. J., Kwo, P. Y., & Helft, P. R. (2014). Ethical Considerations Surrounding Survival Benefit-Based Liver Allocation. LIVER TRANSPLANTATION, 20(2), 140–46.

De novo malignancy post-liver transplantation: a single center, population controlled study
Chatrath, H., Berman, K., Vuppalanchi, R., Slaven, J., Kwo, P., Tector, A. J., … Ghabril, M. (2013). De novo malignancy post-liver transplantation: a single center, population controlled study. CLINICAL TRANSPLANTATION, 27(4), 582–90.

Oral Direct-Acting Antiviral Therapy to Prevent Reinfection of the Liver Graft After Liver Transplantation for Hepatitis C Virus-Related Cirrhosis
Kwo, P. Y., & Tector, A. J. (2013). Oral Direct-Acting Antiviral Therapy to Prevent Reinfection of the Liver Graft After Liver Transplantation for Hepatitis C Virus-Related Cirrhosis. LIVER TRANSPLANTATION, 19(7), 780–81.

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
Lawitz, E., Sulkowski, M., Jacobson, I., Kraft, W. K., Maliakkal, B., Al-Ibrahim, M., … Mobashery, N. (2013). Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. ANTIVIRAL RESEARCH, 99(3), 214–20.

The Liver in Oncology.
Dhanasekaran, R., & Kwo, P. Y. (2017). The Liver in Oncology. Clinics in Liver Disease, 21(4), 697–707.

Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.
Cholankeril, G., Gonzalez, H. C., Satapathy, S., Gonzalez, S. A., Hu, M., Khan, M. A., … Ahmed, A. (2018). Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association.

Alcohol Liver Disease is now the most rapidly rising Indication for Liver Transplant Waitlist Registration in the United States
Rahim, U., Cholankeril, G., Yoo, E. R., Liu, A., Li, A. A., Kim, D., … Goel, A. (2017). Alcohol Liver Disease is now the most rapidly rising Indication for Liver Transplant Waitlist Registration in the United States. HEPATOLOGY. WILEY.

SHORT DURATION TREATMENT WITH SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN TREATMENT-NAIVE GENOTYPE 1-6 HCV-INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS
Gane, E. J., Nguyen, M., Kwo, P., Kowdley, K., Reau, N., Jacobson, I., … Lawitz, E. (2016). SHORT DURATION TREATMENT WITH SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN TREATMENT-NAIVE GENOTYPE 1-6 HCV-INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation.
Kwong, A., Wall, A., Melcher, M., Wang, U., Ahmed, A., Khush, K., … Kwo, P. (2018). Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation. AMERICAN JOURNAL OF TRANSPLANTATION. WILEY.

Pragmatic Surgical Risk Assessment Criteria in Critically Ill Patients Prior to Liver Transplantation.
Bonham, C., Tulu, Z., Melcher, M., Kwo, P., Concepcion, W., Ahmed, A., & Esquivel, C. (2018). Pragmatic Surgical Risk Assessment Criteria in Critically Ill Patients Prior to Liver Transplantation. AMERICAN JOURNAL OF TRANSPLANTATION. WILEY.

Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis
Flamm, S. L., Wyles, D. L., Wang, S., Mutimer, D. J., Rockstroh, J. K., Horsmans, Y. J., … Mensa, F. J. (2017). Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis. HEPATOLOGY, 66, 35A–36A.

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., … Mensa, F. J. (2018). Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. NEW ENGLAND JOURNAL OF MEDICINE, 378(4), 354–69.

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
Wyles, D., Poordad, F., Wang, S., Alric, L., Felizarta, F., Kwo, P. Y., … Mensa, F. J. (2018). Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. HEPATOLOGY, 67(2), 514–23.

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment
Sinclair, S. M., Jones, J. K., Miller, R. K., Greene, M. F., Kwo, P. Y., & Maddrey, W. C. (2017). The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment. DRUG SAFETY, 40(12), 1205–18.

A Prognostic Model for Liver Transplant Candidates with Hepatitis C - A Decision Aid for Antiviral Therapy
Lee, H. W., Mannalithara, A., Asrani, S. K., Biggins, S. W., Heimbach, J., Brandman, D., … Kim, W. R. (2017). A Prognostic Model for Liver Transplant Candidates with Hepatitis C - A Decision Aid for Antiviral Therapy. HEPATOLOGY, 66, 548A–549A.

Real World Effectiveness of 8 vs 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts
Wilson, E., Davitkov, P., Kwo, P. Y., Kattakuzhy, S., Qureshi, K., Sundaram, V., … Kowdley, K. V. (2017). Real World Effectiveness of 8 vs 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts. HEPATOLOGY, 66, 608A.

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong
Kwo, P. Y., Shiffman, M. L., & Bernstein, D. E. (2018). The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong. AMERICAN JOURNAL OF GASTROENTEROLOGY, 113(1), 2–4.

Efficacy and safety of elbasvir/ grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy
Dore, G., Hezode, C., Kwo, P., Sperl, J., Hwang, P., Long, J., … Haber, B. (2018). Efficacy and safety of elbasvir/ grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy. JOURNAL OF VIRAL HEPATITIS. WILEY.

Response to Perrella et al.
Kwo, P. Y., Shiffman, M. L., & Bernstein, D. E. (2018). Response to Perrella et al. The American Journal of Gastroenterology.

Initial Uptake and Time to Treatment of all Oral Direct Acting Antivirals for Hepatitis C
Kwo, P., Zhang, Z., Knapp, K., Hui, S. L., Kelley, A., Muschi, D., & Puenpatom, A. (2017). Initial Uptake and Time to Treatment of all Oral Direct Acting Antivirals for Hepatitis C. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112, S502.

Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment.
Charville, G. W., Padda, S. K., Sibley, R. K., Puthillath, A., & Kwo, P. Y. (2018). Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment. Case Reports in Hepatology, 2018, 3413592.

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Reau, N., Kwo, P. Y., Rhee, S., Brown, R. S., Agarwal, K., Angus, P., … Forns, X. (2018). Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. HEPATOLOGY, 68(4), 1298–1307.

Treatment of Hepatitis B in the Us; Real-World Evidence from the Trio Network
Bae, H., Curry, M. P., Dieterich, D. T., Ankoma-Sey, V., Reddy, K. R., Pan, C. Q., … Afdhal, N. H. (2018). Treatment of Hepatitis B in the Us; Real-World Evidence from the Trio Network. HEPATOLOGY, 68, 264A–265A.

Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice; Real-World Evidence from the Trio Network
Curry, M. P., Bae, H., Dieterich, D. T., Ankoma-Sey, V., Reddy, K. R., Pan, C. Q., … Afdhal, N. H. (2018). Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice; Real-World Evidence from the Trio Network. HEPATOLOGY, 68, 252A.

Liver Transplantation for HCV Non-Viremic Recipients with HCV Viremic Donors.
Kwong, A. J., Wall, A., Melcher, M., Wang, U., Ahmed, A., Subramanian, A., & Kwo, P. Y. (2018). Liver Transplantation for HCV Non-Viremic Recipients with HCV Viremic Donors. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

PROOF OF CONCEPT STUDY OF AN APOPTOSIS-SIGNAL REGULATING KINASE (ASK1) INHIBITOR (SELONSERTIB) IN COMBINATION WITH AN ACETYL-COA CARBOXYLASE INHIBITOR (GS-0976) OR A FARNESOID X RECEPTOR (FXR) AGONIST (GS-9674) IN NASH
Lawitz, E., Herring, R., Younes, Z. H., Gane, E., Ruane, P. J., Aguilar, R., … Harrison, S. A. (2018). PROOF OF CONCEPT STUDY OF AN APOPTOSIS-SIGNAL REGULATING KINASE (ASK1) INHIBITOR (SELONSERTIB) IN COMBINATION WITH AN ACETYL-COA CARBOXYLASE INHIBITOR (GS-0976) OR A FARNESOID X RECEPTOR (FXR) AGONIST (GS-9674) IN NASH. SWISS MEDICAL WEEKLY, 148, 24S.

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals
Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., … Gane, E. (2016). High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals. AMERICAN JOURNAL OF GASTROENTEROLOGY, 111, S380.

HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS
Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., … Gane, E. J. (2016). HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Diagnosis and Management of Primary Biliary Cholangitis.
Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., & Jacobson, I. M. (2018). Diagnosis and Management of Primary Biliary Cholangitis. The American Journal of Gastroenterology.

Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis.
Flamm, S., Mutimer, D., Asatryan, A., Wang, S., Rockstroh, J., Horsmans, Y., … Wyles, D. L. (2018). Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis. Journal of Viral Hepatitis.

Daclatasvir and Sofosbuvir Treatment of Decompensated Liver Disease or Post-Liver Transplant Hepatitis C Virus Recurrence in Patients With Advanced Liver Disease/Cirrhosis in a Real-World Cohort
Kwo, P., Fried, M. W., Reddy, K. R., Soldevila-Pico, C., Khemichian, S., Darling, J., … Brown, R. S. (2018). Daclatasvir and Sofosbuvir Treatment of Decompensated Liver Disease or Post-Liver Transplant Hepatitis C Virus Recurrence in Patients With Advanced Liver Disease/Cirrhosis in a Real-World Cohort. HEPATOLOGY COMMUNICATIONS, 2(4), 354–63.

The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer.
Wong, K., Ozeki, K., Kwong, A., Patel, B. N., & Kwo, P. (2018). The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer. PloS One, 13(12), e0208233.

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
Naganuma, A., Chayama, K., Notsumata, K., Gane, E., Foster, G. R., Wyles, D., … Kumada, H. (2019). Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. Journal of Gastroenterology.

Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy
Hezode, C., Kwo, P., Sperl, J., Dore, G., Hwang, P., Long, J., … Haber, B. (2018). Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis
Poordad, F., Zeuzem, S., Asatryan, A., Foster, G., Gane, E., Wyles, D., … Mensa, F. (2018). Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Drug-drug interactions in hepatitis C virus treatment: Do they really matter?
Ahmed, A., Lutchman, G. A., & Kwo, P. Y. (2017). Drug-drug interactions in hepatitis C virus treatment: Do they really matter? Clinical Liver Disease, 10(5), 111–15.

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Wyles, D., Poordad, F., Wang, S., Alric, L., Felizarta, F., Kwo, P. Y., … Mensa, F. J. (2017). Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology (Baltimore, Md.).

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies
Yao, B., Asselah, T., Fredrick, L., Schnell, G., Kowdley, K. V., Kwo, P., … Mensa, F. (2019). Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Ma, X., Lalezari, J., Tuan Nguyen, Bae, H., Schiff, E. R., Fung, S., … Lopatin, U. (2019). Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. JOURNAL OF HEPATOLOGY, 70, E130.

Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice
Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, V., Reddy, R., Pan, C., … Afdhal, N. (2019). Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice. JOURNAL OF HEPATOLOGY, 70, E462.

A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis
Lawitz, E., Gane, E., Ruane, P., Herring, J. R., Younes, Z. H., Kwo, P., … Loomba, R. (2019). A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Diagnosis and Management of Primary Biliary Cholangitis
Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., & Jacobson, I. M. (2019). Diagnosis and Management of Primary Biliary Cholangitis. AMERICAN JOURNAL OF GASTROENTEROLOGY, 114(1), 48–63.

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
Flamm, S., Mutimer, D., Asatryan, A., Wang, S., Rockstroh, J., Horsmans, Y., … Wyles, D. L. (2019). Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. JOURNAL OF VIRAL HEPATITIS, 26(3), 337–49.

Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014.
Kim, D., Cholankeril, G., Li, A. A., Kim, W., Tighe, S. P., Hameed, B., … Ahmed, A. (2019). Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014. Liver International : Official Journal of the International Association for the Study of the Liver.

The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer
Wong, K., Ozeki, K., Kwong, A., Patel, B. N., & Kwo, P. (2018). The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer. PLOS ONE, 13(12).

Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors
Kwong, A. J., Wall, A., Melcher, M., Wang, U., Ahmed, A., Subramanian, A., & Kwo, P. Y. (2019). Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. AMERICAN JOURNAL OF TRANSPLANTATION, 19(5), 1380–87.

EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: AN INTEGRATED ANALYSIS OF PHASE 2 AND 3 STUDIES
Yao, B. B., Asselah, T., Frederick, L., Schnell, G., Kowdley, K., Kwo, P. Y., … Lee, S. S. (2019). EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: AN INTEGRATED ANALYSIS OF PHASE 2 AND 3 STUDIES. GUT. BMJ PUBLISHING GROUP.

Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
Sripongpun, P., Mannalithara, A., Kwo, P. Y., & Kim, W. R. (2019). Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association.

Using Liver Transplant (LT) Data And Analytics to Improve Program Clinical and Financial Performance.
Bonham, A., Tulu, Z., Concepcion, W., Gallo, A., Melcher, M., Kwo, P., … Esquivel, C. (2019). Using Liver Transplant (LT) Data And Analytics to Improve Program Clinical and Financial Performance. AMERICAN JOURNAL OF TRANSPLANTATION. WILEY.

CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US
Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, Reddy, R., Pan, C., … Afdhal, N. (2019). CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US. VALUE IN HEALTH. ELSEVIER SCIENCE INC.

y Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
Naganuma, A., Chayama, K., Notsumata, K., Gane, E., Foster, G. R., Wyles, D., … Kumada, H. (2019). y Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. JOURNAL OF GASTROENTEROLOGY, 54(8), 752–61.

Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease.
Adejumo, A. C., Kim, D., Iqbal, U., Yoo, E. R., Boursiquot, B. C., Cholankeril, G., … Ahmed, A. (2019). Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. Journal of Palliative Medicine.

Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
Kwo, P. Y., Puenpatom, A., Zhang, Z., Hui, S. L., Kelley, A. A., & Muschi, D. (2019). Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PloS One, 14(8), e0218759.

iLFT: A big assist in the recognition of liver disease in general practice.
Cheung, A. C., & Kwo, P. Y. (2019). iLFT: A big assist in the recognition of liver disease in general practice. Journal of Hepatology.

DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist Response
Kwo, P. Y., Shiffman, M. L., & Bernstein, D. E. (2018). DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist Response. AMERICAN JOURNAL OF GASTROENTEROLOGY, 113(8), 1251–52.

Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis
Cholankeril, G., Gonzalez, H. C., Satapathy, S. K., Gonzalez, S. A., Hu, M., Khan, M. A., … Ahmed, A. (2018). Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 16(6), 965-+.

Toward Elimination of Hepatitis C Infection: How Bestto Address Gaps in the Cascade of Care?
Prabhakar, V., & Kwo, P. Y. (2019). Toward Elimination of Hepatitis C Infection: How Bestto Address Gaps in the Cascade of Care? Hepatology Communications, 3(9), 1174–76.

Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014
Kim, D., Cholankeril, G., Li, A. A., Kim, W., Tighe, S. P., Hameed, B., … Ahmed, A. (2019). Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. LIVER INTERNATIONAL, 39(9), 1661–71.

CLINICOPATHOLOGICAL FEATURES OF NONALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC)
Arjunan, V., Prabhakar, V., Raghavan, S. S., Tulu, Z., Kambham, N., Ahmed, A., … Dhanasekaran, R. (2019). CLINICOPATHOLOGICAL FEATURES OF NONALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC). HEPATOLOGY, 70, 548A.

IS IT GOOD IDEA TO OFFER TRANSPLANT EXCEPTION POINTS FOR SEPTUAGENARIANS WITH HEPATOCELLULAR CARCINOMA (HCC)?
Arjunan, V., Prabhakar, V., Raghavan, S. S., Tulu, Z., Kambham, N., Ahmed, A., … Dhanasekaran, R. (2019). IS IT GOOD IDEA TO OFFER TRANSPLANT EXCEPTION POINTS FOR SEPTUAGENARIANS WITH HEPATOCELLULAR CARCINOMA (HCC)? HEPATOLOGY, 70, 557A–558A.

THE ROLE OF LOCOREGIONAL THERAPY (LRT), POST LRT IMAGING, AND EXPLANT PATHOLOGY AS PREDICTORS OF HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANT (OLT)
Prabhakar, V., Dhanasekaran, R., Arjunan, V., Tulu, Z., Ahmed, A., Daugherty, T., … Kwo, P. Y. (2019). THE ROLE OF LOCOREGIONAL THERAPY (LRT), POST LRT IMAGING, AND EXPLANT PATHOLOGY AS PREDICTORS OF HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANT (OLT). HEPATOLOGY. WILEY.

DIFFERENTIAL TENOFOVIR ALAFENAMIDE (TAF) ADOPTION IN HBV-INFECTED POPULATIONS; ASSESSMENT OF CARE IN US CLINICAL PRACTICE
Curry, M. P., Bae, H. S., Dieterich, D. T., Ankoma-Sey, V., Reddy, K. R., Pan, C. Q., … Afdhal, N. H. (2019). DIFFERENTIAL TENOFOVIR ALAFENAMIDE (TAF) ADOPTION IN HBV-INFECTED POPULATIONS; ASSESSMENT OF CARE IN US CLINICAL PRACTICE. HEPATOLOGY, 70, 308A–309A.

LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA SUPPRESSION
Reddy, K. R., Curry, M. P., Bae, H. S., Dieterich, D. T., Ankoma-Sey, V., Pan, C. Q., … Afdhal, N. H. (2019). LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA SUPPRESSION. HEPATOLOGY, 70, 309A.

CHANGING POPULATION OF LIVER TRANSPLANT RECIPIENTS IN THE ERA OF DIRECT ACTING ANTIVIRAL THERAPY FOR HEPATITIS C VIRUS INFECTION
Xie, C., Abdallah, M., Wong, R. J., Kwo, P. Y., Thuluvath, P., Asrani, S. K., & Singal, A. K. (2019). CHANGING POPULATION OF LIVER TRANSPLANT RECIPIENTS IN THE ERA OF DIRECT ACTING ANTIVIRAL THERAPY FOR HEPATITIS C VIRUS INFECTION. HEPATOLOGY, 70, 679A.

HEP B CONSULT: A POINT-OF-CARE INTERACTIVE DECISION SUPPORT TOOL DELIVERS REAL-TIME, PERSONALIZED, GUIDELINE-BASED TEACHING AND REVEALS VARIANCE BETWEEN CLINICIANS AND GUIDELINES IN THE MANAGEMENT OF HBV INFECTION
Schwartz, Z., Schulz, J., King, E., Agarwal, K., Wong, G. L., & Kwo, P. Y. (2019). HEP B CONSULT: A POINT-OF-CARE INTERACTIVE DECISION SUPPORT TOOL DELIVERS REAL-TIME, PERSONALIZED, GUIDELINE-BASED TEACHING AND REVEALS VARIANCE BETWEEN CLINICIANS AND GUIDELINES IN THE MANAGEMENT OF HBV INFECTION. HEPATOLOGY. WILEY.

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy.
Hezode, C., Kwo, P., Sperl, J., Hwang, P., Long, J., Talwani, R., … Haber, B. A. (2019). Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy. International Journal of Women's Health, 11, 617–28.

CONTINUED THERAPY WITH ABI-H0731+NRTI RESULTS IN SEQUENTIAL REDUCTION/LOSS OF HBV DNA, HBV RNA, HBeAg, HBcrAg AND HBsAg IN HBeAg POSITIVE PATIENTS
Sulkowski, M. S., Agarwal, K., Fung, S. K., Yuen, M.-F., Ma, X., Lalezari, J. P., … Colonno, R. (2019). CONTINUED THERAPY WITH ABI-H0731+NRTI RESULTS IN SEQUENTIAL REDUCTION/LOSS OF HBV DNA, HBV RNA, HBeAg, HBcrAg AND HBsAg IN HBeAg POSITIVE PATIENTS. HEPATOLOGY, 70(6), 1486A–1487A.

Novel use of endoscopic morcellator to clear large obscuring clot in patient with upper-GI bleed.
Gubatan, J., Kwo, P., & Hwang, J. H. (2020). Novel use of endoscopic morcellator to clear large obscuring clot in patient with upper-GI bleed. VideoGIE : an Official Video Journal of the American Society for Gastrointestinal Endoscopy, 5(2), 58–60.

Sustained Decline of Noninvasive Fibrosis Index Values in Patients With Chronic Hepatitis C (CHC) With Sustained Virologic Response (SVR) After Receiving Direct-Acting Antiviral Agents (DAAs)
Prabhakar, V., Lutchman, G., Ahmed, A., Nguyen, M. H., Daugherty, T., & Kwo, P. (2019). Sustained Decline of Noninvasive Fibrosis Index Values in Patients With Chronic Hepatitis C (CHC) With Sustained Virologic Response (SVR) After Receiving Direct-Acting Antiviral Agents (DAAs). AMERICAN JOURNAL OF GASTROENTEROLOGY, 114, S553–S554.

Novel Use of EndoRotor (R) Device to Clear Large Obscuring Clot in Patient With Upper Gastrointestinal Bleed
Gubatan, J., Kwo, P., & Hwang, J. H. (2019). Novel Use of EndoRotor (R) Device to Clear Large Obscuring Clot in Patient With Upper Gastrointestinal Bleed. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter?
Kwong, A. J., & Kwo, P. Y. (2020). Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter? Alimentary Pharmacology & Therapeutics, 51(7), 739–40.

Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure.
Saab, S., Bernstein, D., Hassanein, T., Kugelmas, M., & Kwo, P. (2020). Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. Journal of Clinical Gastroenterology.

DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna, E. C., Morelli, G., Terrault, N. A., Lok, A. S., Lim, J. K., Di Bisceglie, A. M., … Reddy, K. R. (2020). DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. Journal of Hepatology.

A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis
Lawitz, E., Gane, E., Ruane, P., Herring, R., Younes, Z. H., Kwo, P., … Loomba, R. (2019). A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis. SWISS MEDICAL WEEKLY. E M H SWISS MEDICAL PUBLISHERS LTD.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5/6: An Integrated Analysis of Phase 2/3 Studies.
Yao, B. B., Fredrick, L. M., Schnell, G., Kowdley, K. V., Kwo, P. Y., Poordad, F., … Asselah, T. (2020). Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5/6: An Integrated Analysis of Phase 2/3 Studies. Liver International : Official Journal of the International Association for the Study of the Liver.

HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL
Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, Reddy, R., Pan, C., … Afdhal, N. (2020). HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL. VALUE IN HEALTH. ELSEVIER SCIENCE INC.

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials.
Nangia, G., Vierling, J. M., Kwo, P., Brown, D. D., Klopfer, S. O., Robertson, M. N., … Reddy, K. R. (2020). Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials. Journal of Viral Hepatitis.

Viral Hepatitis Other than A, B, and C: Evaluation and Management.
Cheung, A., & Kwo, P. (2020). Viral Hepatitis Other than A, B, and C: Evaluation and Management. Clinics in Liver Disease, 24(3), 405–19.

Sustained Virologic Remission in an 8-Month-Old Pediatric Patient with Carbamoyl Phosphate Synthetase I Deficiency and Hepatitis C Infection Using Direct Acting Antivirals Prior to Liver Transplant.
Huang, A. C., Beadles, A., Romero, D., Berquist, W., Bensen, R., Kwo, P., & Mckenzie, R. B. (2020). Sustained Virologic Remission in an 8-Month-Old Pediatric Patient with Carbamoyl Phosphate Synthetase I Deficiency and Hepatitis C Infection Using Direct Acting Antivirals Prior to Liver Transplant. Journal of Pediatric Gastroenterology and Nutrition.

Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study.
Kim, D., Adeniji, N., Latt, N., Kumar, S., Bloom, P. P., Aby, E. S., … Dhanasekaran, R. (2020). Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association.

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis.
Kwo, P., & Dronamraju, D. (2020). More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis. Clinical and Molecular Hepatology.

Improving Liver Transplant (LT) Waitlist Attrition
Concepcion, W., Ahmed, A., Tulu, Z., Hogan, L., Bonham, A., Gallo, A., … Esquivel, C. (2020). Improving Liver Transplant (LT) Waitlist Attrition. AMERICAN JOURNAL OF TRANSPLANTATION. WILEY.

Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-Transplant Clinical Outcome.
Adeniji, N., Arjunan, V., Prabhakar, V., Tulu, Z., Kambham, N., Ahmed, A., … Dhanasekaran, R. (2020). Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-Transplant Clinical Outcome. Clinical Transplantation, e14128.

THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS NOT MEETING CRITERIA FOR ANTIVIRAL THERAPY
Alshuwaykh, O., Goel, A., Daugherty, T., Cheung, A., Kim, W. R., Kwong, A. J., … Kwo, P. Y. (2020). THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS NOT MEETING CRITERIA FOR ANTIVIRAL THERAPY. HEPATOLOGY. WILEY.

PREDICTORS OF OUTCOMES OF COVID-19 IN PATIENTS WITH CHRONIC LIVER DISEASE: US MULTI-CENTER STUDY
Adeniji, N., Kim, D., Latt, N. L., Kumar, S., Bloom, P. P., Aby, E. S., … Dhanasekaran, R. (2020). PREDICTORS OF OUTCOMES OF COVID-19 IN PATIENTS WITH CHRONIC LIVER DISEASE: US MULTI-CENTER STUDY. HEPATOLOGY. WILEY.

OUTCOMES AFTER HOSPITALIZATION WITH ACUTE DECOMPENSATION DUE TO ALCOHOL-RELATED LIVER DISEASE
Kwong, A. J., Goel, A., Daugherty, T., Kwo, P. Y., & Kim, W. R. (2020). OUTCOMES AFTER HOSPITALIZATION WITH ACUTE DECOMPENSATION DUE TO ALCOHOL-RELATED LIVER DISEASE. HEPATOLOGY. WILEY.

ANALYSIS OF LONGER-TERM SAFETY PROFILE OF THE HEPATITIS B VIRUS CORE INHIBITOR ABI-H0731 IN AN OPEN LABEL EXTENSION STUDY
Jacobson, I. M., Ma, X., Tuan Nguyen, Schiff, E. R., Yuen, M.-F., Hann, H.-W. L., … Dieterich, D. T. (2020). ANALYSIS OF LONGER-TERM SAFETY PROFILE OF THE HEPATITIS B VIRUS CORE INHIBITOR ABI-H0731 IN AN OPEN LABEL EXTENSION STUDY. HEPATOLOGY. WILEY.

FEASIBILITY AND EFFICACY OF NOREPINEPHRINE IN THE NON-ICU SETTING FOR TREATMENT OF HEPATORENAL SYNDROME
Kwong, A. J., Cheng, X., Kwo, P. Y., Wang, U., & Kim, W. R. (2020). FEASIBILITY AND EFFICACY OF NOREPINEPHRINE IN THE NON-ICU SETTING FOR TREATMENT OF HEPATORENAL SYNDROME. HEPATOLOGY. WILEY.

HEPATITIS C SCREENING IN POST-BABY BOOMER GENERATION AMERICANS: ONE SIZE DOES NOT FIT ALL
Sriponapun, P., Kim, W. R., Udompap, P., Mannalithara, A., Kwong, A. J., Goel, A., & Kwo, P. Y. (2020). HEPATITIS C SCREENING IN POST-BABY BOOMER GENERATION AMERICANS: ONE SIZE DOES NOT FIT ALL. HEPATOLOGY. WILEY.

Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients with Chronic Hepatitis B.
Sripongpun, P., Kim, W. R., Mannalithara, A., Kwong, A., Daugherty, T., Goel, A., & Kwo, P. Y. (2020). Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients with Chronic Hepatitis B. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association.

Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
Younossi, Z. M., Noureddin, M., Bernstein, D., Kwo, P., Russo, M., Shiffman, M. L., … Abdelmalek, M. (2020). Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. The American Journal of Gastroenterology.

Post-Transplant Outcomes in Older Patients with Hepatocellular Carcinoma (HCC) are Driven by non-HCC Factors.
Adeniji, N., Arjunan, V., Prabhakar, V., Mannalithara, A., Ghaziani, T., Ahmed, A., … Dhanasekaran, R. (2020). Post-Transplant Outcomes in Older Patients with Hepatocellular Carcinoma (HCC) are Driven by non-HCC Factors. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
Abdallah, M. A., Kuo, Y.-F. F., Asrani, S., Wong, R. J., Ahmed, A., Kwo, P., … Singal, A. K. (2020). Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. Journal of Hepatology.

Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., … Kwo, P. Y. (2020). Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. HEPATOLOGY COMMUNICATIONS.

Clinical Response to Treatment for Acute Kidney Injury (AKI) in Patients With Cirrhosis
John, N., Alshuwaykh, O., Goel, A., Ahmed, A., Cheung, A., Dronamraju, D., … Kwo, P. Y. (2020). Clinical Response to Treatment for Acute Kidney Injury (AKI) in Patients With Cirrhosis. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Characterizing Ascites in Subjects With Nonhepatic Solid Tumors
Alshuwaykh, O., Cheung, A., Goel, A., Dhanasekaran, R., Ahmed, A., Dronamraju, D., … Kwo, P. Y. (2020). Characterizing Ascites in Subjects With Nonhepatic Solid Tumors. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation.
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., … Kwo, P. Y. (2021). Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. Hepatology Communications, 5(3), 516–525.

How Clinicians May Use Tests of Hepatic Function Now and In the Future.
Ghaziani, T. T., & Kwo, P. Y. (2021). How Clinicians May Use Tests of Hepatic Function Now and In the Future. Translational Research : the Journal of Laboratory and Clinical Medicine.

Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome.
Kwong, A., Kim, W. R., Kwo, P. Y., Wang, U., & Cheng, X. (2021). Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Proof-of-concept study of an apoptosis-signal regulating kinase inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in non-alcoholic steatohepatitis
Gane, E., Lawitz, E., Herring, R., Younes, Z. H., Ruane, P. J., Aguilar, R., … Harrison, S. A. (2018). Proof-of-concept study of an apoptosis-signal regulating kinase inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in non-alcoholic steatohepatitis. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY.

Dynamic Visual Processing in Patients with Decompensated Cirrhosis
Wong, K., Liston, D., Papademetriou, S., Yeoh, A., Goel, A., Kwo, P., & Okafor, P. (2018). Dynamic Visual Processing in Patients with Decompensated Cirrhosis. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH
Lawitz, E., Herring, R., Younes, Z. H., Gane, E., Ruane, P., Schall, R. A., … Harrison, S. (2018). Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir +/- dasabuvir and +/- ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3-6)
Agarwal, K., Brown, R. S., Dumas, E. O., McCaughan, G. W., Samuel, D., Terrault, N., … Forns, X. (2017). Safety and efficacy of ombitasvir/paritaprevir/ritonavir +/- dasabuvir and +/- ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3-6). JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study
Vierling, J. M., Sobhonslidsuk, A., Papatheodoridis, G., Assy, N., Rosenberg, W., Guyader, D., … Kwo, P. (2017). Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection
Reau, N., Kwo, P. Y., Rhee, S., Brown, R. S., Agarwal, K., Angus, P., … Forns, X. (2017). MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.

Current and future strategies for the treatment of chronic hepatitis C.
Alshuwaykh, O., & Kwo, P. Y. (2021). Current and future strategies for the treatment of chronic hepatitis C. Clinical and Molecular Hepatology, 27(2), 246–56.

Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat.
Dhanasekaran, R., & Kwo, P. Y. (2021). Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat. Clinical Liver Disease, 17(3), 169–73.

Alcoholic Hepatitis and its Many Facets.
Kwo, P. Y. (2021). Alcoholic Hepatitis and its Many Facets. Clinics in Liver Disease, 25(3), xiii-xiv.

Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection.
Gane, E., Sulkowski, M., Ma, X., Nguyen, T., Hann, H.-W., Hassanein, T., … Yuen, M.-F. (2021). Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection. JOURNAL OF HEPATOLOGY. ELSEVIER.

Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
Singal, A. K., Kwo, P., Kwong, A., Liangpunsakul, S., Louvet, A., Mandrekar, P., … Shah, V. H. (2021). Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. Hepatology (Baltimore, Md.).

THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS WITH CIRRHOSIS NOT MEETING CURRENT TREATMENT GUIDANCE
Alshuwaykh, O., Goel, A., Ghaziani, T. T., Daugherty, T., Dhanasekaran, R., Ahmed, A., … Kwo, P. Y. (2021). THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS WITH CIRRHOSIS NOT MEETING CURRENT TREATMENT GUIDANCE. HEPATOLOGY. WILEY.

PSYCHOSOCIAL PREDICTORS OF ALCOHOL RELAPSE AMONG LIVER TRANSPLANT CANDIDATES WITH ALCOHOL-RELATED LIVER DISEASE
Sedki, M., Kwo, P. Y., Ahmed, A., Hussain, F., Kwong, A. J., & Goel, A. (2021). PSYCHOSOCIAL PREDICTORS OF ALCOHOL RELAPSE AMONG LIVER TRANSPLANT CANDIDATES WITH ALCOHOL-RELATED LIVER DISEASE. HEPATOLOGY. WILEY.

STANFORD INTEGRATED PSYCHOSOCIAL ASSESSMENT FOR TRANSPLANT (SIPAT) IS SUPERIOR TO SALT AND HRAR IN IDENTIFYING LT CANDIDATES WITH ALD AT LOW RISK OF RELAPSE
Sedki, M., Kwo, P. Y., Ahmed, A., Hussain, F., Kwong, A. J., & Goel, A. (2021). STANFORD INTEGRATED PSYCHOSOCIAL ASSESSMENT FOR TRANSPLANT (SIPAT) IS SUPERIOR TO SALT AND HRAR IN IDENTIFYING LT CANDIDATES WITH ALD AT LOW RISK OF RELAPSE. HEPATOLOGY. WILEY.

PREDICTORS OF ELEVATED LIVER TESTS DURING COVID-19 SHELTER IN PLACE IN CHRONIC LIVER DISEASE PATIENTS
Alshuwaykh, O., Wong, R. J., Kim, W. R., Torok, N. J., Jiang, J. K., & Kwo, P. Y. (2021). PREDICTORS OF ELEVATED LIVER TESTS DURING COVID-19 SHELTER IN PLACE IN CHRONIC LIVER DISEASE PATIENTS. HEPATOLOGY. WILEY.

HBV PGRNA AND DNA BOTH REBOUND IMMEDIATELY FOLLOWING DISCONTINUATION OF THE CORE INHIBITOR VEBICORVIR DESPITE CONTINUED NRTI TREATMENT IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B VIRUS INFECTION: FINDINGS FROM A PHASE 2 OPEN LABEL STUDY
Yuen, M.-F., Ma, X., Hassanein, T. I., Kwo, P. Y., Ma, J., Li, L., … Agarwal, K. (2021). HBV PGRNA AND DNA BOTH REBOUND IMMEDIATELY FOLLOWING DISCONTINUATION OF THE CORE INHIBITOR VEBICORVIR DESPITE CONTINUED NRTI TREATMENT IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B VIRUS INFECTION: FINDINGS FROM A PHASE 2 OPEN LABEL STUDY. HEPATOLOGY. WILEY.

IMPACT OF NEW SIMULTANEOUS LIVER KIDNEY ALLOCATION POLICY ON POST LIVER TRANSPLANT OUTCOMES AND NUMBER OF KIDNEYS USED
Waleed, M., Maan, M. H. A., Kuo, Y.-F., Kwo, P. Y., Mahmud, N., Sharma, P., … Singal, A. K. (2021). IMPACT OF NEW SIMULTANEOUS LIVER KIDNEY ALLOCATION POLICY ON POST LIVER TRANSPLANT OUTCOMES AND NUMBER OF KIDNEYS USED. HEPATOLOGY. WILEY.

Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.
Pan, C. Q., Jacobson, I. M., Martin, P., Kwo, P., Lim, J., Han, S.-H. B., … Tong, M. J. (1800). Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination. Hepatology (Baltimore, Md.).

Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study.
Halket, D., Dang, J., Phadke, A., Jayasekera, C., Kim, W. R., Kwo, P., … Goel, A. (2022). Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study. Journal of General Internal Medicine.

Blood phosphatidylethanol testing and liver transplant eligibility selection: A step closer.
Singal, A. K., & Kwo, P. (2022). Blood phosphatidylethanol testing and liver transplant eligibility selection: A step closer. Alcoholism, Clinical and Experimental Research.

First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Pan, C. Q., Afdhal, N. H., Ankoma-Sey, V., Bae, H., Curry, M. P., Dieterich, D., … Reddy, K. R. (2022). First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatology Communications.

Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization.
Singal, A. K., Kuo, Y.-F., Kwo, P., Mahmud, N., Sharma, P., & Nadim, M. K. (2022). Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization. Clinical Transplantation, e14700.

Building a better mousetrap: can MELD-Na be improved?
Kwong, A., Mannalithara, A., Kwo, P., & Kim, W. R. (2020). Building a better mousetrap: can MELD-Na be improved? JOURNAL OF HEPATOLOGY. ELSEVIER.

Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US
Sripongpun, P., Goel, A., Mannalithara, A., Kwo, P., & Kim, W. R. (2020). Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US. JOURNAL OF HEPATOLOGY. ELSEVIER.

Leveraging direct-to-patient messaging: electronic record assimilation and subsequent eradication of hepatitis C (Erase-C)
Goel, A., Downing, L., Dang, J., Jayasekera, C., & Kwo, P. (2020). Leveraging direct-to-patient messaging: electronic record assimilation and subsequent eradication of hepatitis C (Erase-C). JOURNAL OF HEPATOLOGY. ELSEVIER.

Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice
Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, V., Reddy, R., Pan, C., … Afdhal, N. (2020). Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice. JOURNAL OF HEPATOLOGY. ELSEVIER.

Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
Fung, S., Sulkowski, M., Lalezari, J., Schiff, E. R., Dieterich, D., Hassanein, T., … Yuen, M.-F. (2020). Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection. JOURNAL OF HEPATOLOGY. ELSEVIER.

Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression
Reddy, R., Curry, M., Dieterich, D., Ankoma-Sey, V., Pan, C., Hann, H.-W., … Afdhal, N. (2020). Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression. JOURNAL OF HEPATOLOGY. ELSEVIER.

Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection.
Sulkowski, M. S., Agarwal, K., Ma, X., Nguyen, T. T., Schiff, E. R., Hann, H.-W. L., … Yuen, M.-F. (2022). Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection. Journal of Hepatology.

Utilization and outcomes of hepatitis B-positive grafts in orthotopic liver transplantation in the United States, 1999-2021.
Ali, S. E., Vutien, P., Bonham, C. A., Landis, C., Kwo, P., Esquivel, C., & Nguyen, M. H. (2022). Utilization and outcomes of hepatitis B-positive grafts in orthotopic liver transplantation in the United States, 1999-2021. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.